Genmab Balance Sheet Health
Financial Health criteria checks 6/6
Genmab has a total shareholder equity of DKK32.5B and total debt of DKK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are DKK36.7B and DKK4.2B respectively. Genmab's EBIT is DKK5.7B making its interest coverage ratio -5.6. It has cash and short-term investments of DKK29.6B.
Key information
0%
Debt to equity ratio
kr.0
Debt
Interest coverage ratio | -5.6x |
Cash | kr.29.58b |
Equity | kr.32.50b |
Total liabilities | kr.4.18b |
Total assets | kr.36.68b |
Recent financial health updates
No updates
Recent updates
Genmab: A Complicated Tale
May 01Genmab Acquires A Missing Piece For Its Pipeline
Apr 16Genmab: Recent Updates Support The Growth Narrative
Feb 21Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)
Jan 23Genmab: 3 Trends To Track For A Strong 2024 And Beyond
Jan 12Genmab reports Q3 worldwide sales of $2.05B for Darzalex
Oct 18Genmab improves FY 2022 guidance
Aug 08Genmab reports Q2 worldwide net sales of DARZALEX $1.99B
Jul 19Genmab: A Royalty Powerhouse With A Strong Pipeline
Jun 28Genmab: Looking For Growth At A Reasonable Price
Jun 10Genmab: A Biotech Company On The Rise
Mar 12Genmab: Ready For More Growth In 2022
Dec 23Genmab: Monoclonal Antibody Experts, Low Risk Business Model
Aug 18Financial Position Analysis
Short Term Liabilities: GMAB's short term assets (DKK34.4B) exceed its short term liabilities (DKK2.8B).
Long Term Liabilities: GMAB's short term assets (DKK34.4B) exceed its long term liabilities (DKK1.4B).
Debt to Equity History and Analysis
Debt Level: GMAB is debt free.
Reducing Debt: GMAB had no debt 5 years ago.
Debt Coverage: GMAB has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GMAB has no debt, therefore coverage of interest payments is not a concern.